OP
IBRX icon

ORG Partners’s ImmunityBio IBRX Stock Holding History

ORG Partners’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.62K Sell
1,325
-925
-41% -$2.1K ﹤0.01% 1391
2025
Q3 		$5.54K Buy
2,250
+1,100
+96% +$2.83K ﹤0.01% 1112
2025
Q2 		$2.96K Buy
+1,150
New +$3.09K ﹤0.01% 1152

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

ORG Partners's IBRX Position: Q4 2025 in Review

ORG Partners reduced its ImmunityBio (IBRX) stake by 41% in Q4 2025, selling an estimated $2.1K and leaving 1,325 shares worth $2.62K. The position accounts for ﹤0.01% of the portfolio, ranked #1391.

ORG Partners first reported a position in IBRX in Q2 2025 and has held it in 3 quarters since. The position peaked at $5.54K in Q3 2025. 276 funds tracked by Wall St. Rank hold IBRX as of Q4 2025.

  • ORG Partners held 1,325 shares of ImmunityBio worth $2.62K as of Q4 2025.
  • ORG Partners sold 925 ImmunityBio shares in Q4 2025, an estimated $2.1K.
  • ImmunityBio made up ﹤0.01% of ORG Partners's portfolio in Q4 2025, its #1391 holding.
  • ORG Partners first reported a position in ImmunityBio in Q2 2025 and has held it in 3 quarters since.
  • ORG Partners's ImmunityBio position peaked at $5.54K in Q3 2025.
  • 276 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2025.

Based on ORG Partners's 13F filing for Q4 2025, filed 14 Jan 2026.